Certara is the global leader in model-informed drug development and regulatory science, focused on optimizing drug development and improving health outcomes.

Certara is the leading provider of model-informed drug development technology and services, as well as a best-in-class provider of regulatory science, writing, and submission management software and services. Certara’s solutions help inform the drug development and regulatory approval process and address the key efficacy, safety, productivity and commercial challenges facing the biopharma industry. The Company serves 1,200 commercial companies, 250 academic institutions and numerous regulatory agencies, across 60 countries. Certara is headquartered in Princeton, New Jersey with over 850 employees globally, including key operations and senior management in Northern Europe.

To Certara

Market trends and drivers

Certara operates in fast-growing, niche markets which address critical needs for Certara’s pharma clients. Biosimulation market growth is driven by pharma clients’ need to optimize R&D spend, as well growing regulatory acceptance of model-informed drug development techniques. Regulatory science growth is driven by increasing outsourcing of regulatory writing and the increasing complexity of the regulatory approval process.

Investment potential

EQT VII is keen to support the continued growth of Certara, both domestically and internationally, particularly through continued investment in next generation technology, further international expansion and complementary acquisitions.

Societal contribution

The icons illustrate the portfolio companies' positive societal contributions based on their solutions i.e. how their products and/or services solve key challenges expressed as the Sustainable Development Goals (SDGs)

Board of Directors

Sheri McCoy Chairperson
Eric Liu Board member
Edmundo Muniz Board member
William Klitgaard Board member
Mason Slaine Board member
James Cashman Board member
Steve McLean Board member

Management

William Feehery CEO
Andrew Schemick CFO